Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences at Stanford University, and is an investigator at the Howard Hughes Medical Institute. She earned a B.A. in chemistry from Harvard University and a Ph.D. from the University of California at Berkeley.
Bertozzi is the founder of bioorthogonal chemistry, a subfield of chemistry that allows scientists to modify molecules in living organisms without disrupting processes occurring within the cells. She has also worked extensively to study how viruses can bind to sugars, known as glycobiology. Her work on the interactions of sugar within the body, and diseases such as arthritis, tuberculosis and cancer, have yielded critical insights with implications across medical specialties.
She has also provided important leadership in the field. She is founder or co-founder of companies such as Thios Pharmaceuticals, Redwood Bioscience, Enable Biosciences, Palleon Pharma, InterVenn Biosciences, Grace Science Foundation, OliLux Biosciences and Lycis Therapeutics.
She has over 600 research publications, including “Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality”, and “Glycans in cancer and inflammation—potential for therapeutics and diagnostics”.
Bertozzi received the MacArthur Genius Grant at age 33, In 2010, she became the first woman to receive the prestigious Lemelson-MIT Prize faculty award. Most recently, Bertozzi was honored with the John J. Carty Award for the Advancement of Science and the Chemistry for the Future Solvay Prize.
Public research university in Berkeley, California, United Statesview profile
Private research university in Cambridge, Massachusetts, United Statesview profile
Private research university located in Stanford, California, United Statesview profile